These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9886458)

  • 1. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide.
    Shaunak S; Wilkins A; Pilling JB; Dick DJ
    J Neurol Neurosurg Psychiatry; 1999 Jan; 66(1):79-81. PubMed ID: 9886458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and management of pergolide-induced fibrosis.
    Agarwal P; Fahn S; Frucht SJ
    Mov Disord; 2004 Jun; 19(6):699-704. PubMed ID: 15197712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.
    Bilici A; Karadag B; Doventas A; Erdincler DS; Cetinkaya S; Ogut G; Tezcan V; Beger T
    Neth J Med; 2004 Nov; 62(10):389-92. PubMed ID: 15683095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
    Jiménez-Jiménez FJ; López-Alvarez J; Sánchez-Chapado M; Montero E; Miquel J; Sierra A; Gutiérrez F
    Clin Neuropharmacol; 1995 Jun; 18(3):277-9. PubMed ID: 8635187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pergolide-induced retroperitoneal fibrosis.
    Mondal BK; Suri S
    Int J Clin Pract; 2000; 54(6):403. PubMed ID: 11092116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.
    Lund BC; Neiman RF; Perry PJ
    Pharmacotherapy; 1999 Dec; 19(12):1437-8. PubMed ID: 10600093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease.
    Kunkler RB; Osborn DE; Abbott RJ
    Br J Urol; 1998 Jul; 82(1):147. PubMed ID: 9698685
    [No Abstract]   [Full Text] [Related]  

  • 8. Pergolide-induced pleuropulmonary fibrosis.
    Bleumink GS; van der Molen-Eijgenraam M; Strijbos JH; Sanwikarja S; van Puijenbroek EP; Stricker BH
    Clin Neuropharmacol; 2002; 25(5):290-3. PubMed ID: 12410064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ergoline-induced retroperitoneal fibrosis].
    Christoffersen CL; Siboni AH; Boisen E; Ladefoged C; Rasmussen C; Christensen-Dalsgaard S; Jakobsen P; Rasmussen LD; Schlander S
    Ugeskr Laeger; 2006 Apr; 168(17):1667; author reply 1667. PubMed ID: 16674890
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease.
    Apostolakis EE; Baikoussis NG; Tselikos D; Koniari I; Prokakis C; Fokaeas E; Karanikolas M
    J Cardiothorac Surg; 2009 Nov; 4():65. PubMed ID: 19912629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
    Roth J; Ulmanová O; Růzicka E
    Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
    Tintner R; Manian P; Gauthier P; Jankovic J
    Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Low dose pergolide induced systemic edema and pleural effusion in a patient with Parkinson's disease].
    Chihara N; Hayakawa M; Yoshimura M; Shiio Y; Nakase H
    Rinsho Shinkeigaku; 2008 Feb; 48(2):143-5. PubMed ID: 18326310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].
    Sánchez-Chapado M; Angulo Cuesta J; Guil Cid M; Jiménez FJ; López Alvarez YJ
    Arch Esp Urol; 1995 Dec; 48(10):979-83. PubMed ID: 8588730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ergoline-induced retroperitoneal fibrosis].
    Munksgaard L; Madsen H; Svolgaard PB; Rasmussen JM
    Ugeskr Laeger; 2006 Feb; 168(9):921-2. PubMed ID: 16513059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Isolated pulmonary hypertension and pergolide].
    Evrard F; Dupuis M; Muller T; Jacquerye P
    Rev Neurol (Paris); 2008 Mar; 164(3):278-9. PubMed ID: 18405780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic pericardial constriction linked to the antiparkinsonian dopamine agonist pergolide.
    Balachandran KP; Stewart D; Berg GA; Oldroyd KG
    Postgrad Med J; 2002 Jan; 78(915):49-50. PubMed ID: 11796875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pergolide in Parkinson's disease: time for a change?
    Grosset KA; Grosset DG
    Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
    [No Abstract]   [Full Text] [Related]  

  • 19. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesulergine and pergolide in previously untreated Parkinson's disease.
    Wright A; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1987 Apr; 50(4):482-4. PubMed ID: 3585362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.